Business
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra (MGL-3196, resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH),
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July 2042.","length":220,"tagName":"p"},{"type":"text","content":"Aramchol is a first-in-class, Phase 3 ready, drug candidate, that showed robust fibrosis improvement in advanced clinical studies.","length":130,"tagName":"p"},{"type":"text","content":"Aramchol's excellent safety and tolerability is a perfect drug candidate to be combined with other MASH drugs, approved or in development.","length":142,"tagName":"p"},{"type":"text","content":"RAMAT-GAN, Israel, Dec. 4, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra (MGL-3196, resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis in South Korea.","length":607,"tagName":"p"},{"type":"image","alt":"Galmed Pharmaceuticals Logo","displaySize":"","headline":null,"caption":"Galmed Pharmaceuticals Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rkpv_HpbOjVKPN_v6KG17Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e","width":400,"height":95}}},{"type":"text","content":"Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH. The new patent extends Aramchol's patent protection worldwide to July 2042, strengthening its leadership in NASH/MASH combination therapy.","length":296,"tagName":"p"},{"type":"text","content":""This patent grant comes at a pivotal moment in the NASH/MASH field, as the industry shifts toward combination therapies to address this complex disease. As commerci...